Skip to content

Understanding Fatty Liver Disease: Symptoms and the Role of Ferritin Levels

CLINICAL PROFILE OF MAFLD PATIENTS AND EVALUATION OF FERRITIN LEVEL AS A MARKER OF SEVERITY - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/104763
Enrollment
85
Registered
2026-02-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Aniruddha M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with MAFLD with or without hepatic fibrosis Both sexes included Age more than 18 years

Exclusion criteria

Exclusion criteria: Patients with medical history, clinical or laboratory evidence of any other liver diseases such as alcoholic or Viral hepatitis, autoimmune liver disease, genetic liver disorders (e.g., Wilson s disease), and drug-induced liver injury and those with decompensated liver cirrhosis Serum ferritin levels more than 1000ng/ml Patients with iron deficiency anemia.

Design outcomes

Primary

MeasureTime frame
The association between baseline serum ferritin levels and severity of MAFLD, assessed by liver fibrosis stage, measured at the time of enrollment .Timepoint: nil

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Raviraja V Acharya

Kasturba Medical College

rvacharya@manipal.edu9845471000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026